Hodogaya Chemical Co., Ltd.
Announcement Regarding Establishment of a Subsidiary
To promote the nucleic acid therapeutics CDMO business, establish subsidiary NuChord (as of September 1, 2026, capital 200 million yen, 100% equity). Build a one-stop production system utilizing the new building and cleanrooms at the Koriyama Plant, aiming to provide services to domestic and international customers. Expected minimal impact on the consolidated results for the fiscal year ending March 2027.
Key Figures
- Capital: 2 hundred million yen
- Establishment date: September 1, 2026
- Shareholding ratio: Our company 100%
AI要約
Purpose of Establishment and Business Concept
This announces the establishment of subsidiary NuChord to enter the nucleic acid therapeutics CDMO business under the medium-term management plan CODE/CHORD 2030. It will provide end-to-end support from raw materials to GMP manufacturing and has built a system to offer one-stop services by constructing a new building and cleanrooms at the Koriyama Plant. In light of collaboration with YGK, future considerations for joint ventures are also suggested.
Impact Going Forward and Disclosure
The impact on the consolidated results for the fiscal year ending March 2027 is expected to be minor, and if significant effects arise, timely disclosure will be made. While this matter does not fall under timely disclosure requirements, it is being voluntarily disclosed to provide information to investors.
Hodogaya Chemical Co., Ltd.
Company overview · Stock price · Financial data · All IR
